帕博利珠单抗联合化疗对比安慰剂联合化疗治疗HER2阴性晚期胃癌(KEYNOTE-859):一项多中心、随机、双盲、3期试验
KEYNOTE-859研究在33个国家207个中心纳入1579例初治HER2阴性局部晚期或转移性胃或胃食管结合部腺癌患者,随机接受帕博利珠单抗或安慰剂联合化疗。在意向治疗人群中,帕博利珠单抗组中位总生存期显著长于安慰剂组(12.9个月 vs 11.5个月;HR 0.78;p<0.0001)。
要点
- 帕博利珠单抗联合化疗较安慰剂联合化疗显著改善HER2阴性晚期胃癌患者总生存期。
- PD-L1 CPS≥1和CPS≥10人群均观察到总生存期获益,CPS≥10人群HR为0.65。
- 安全性可控,未发现新的安全性信号;治疗相关死亡帕博利珠单抗组8例(1%)vs 安慰剂组16例(2%)。
核心结论
- 帕博利珠单抗联合化疗组较安慰剂联合化疗组在意向治疗人群、PD-L1 CPS≥1和CPS≥10人群中均显著改善总生存期,毒性可控。
- 作者认为帕博利珠单抗联合化疗可能成为HER2阴性局部晚期或转移性胃或胃食管结合部腺癌的一线治疗选择。
研究设计与样本
- KEYNOTE-859为多中心、双盲、安慰剂对照、随机3期试验,在33个国家207个医疗中心开展。
- 纳入18岁及以上、既往未治疗、组织学或细胞学确诊的HER2阴性局部晚期或转移性胃或胃食管结合部腺癌、ECOG体能状态评分0或1的患者。
- 共筛选2409例,其中1579例(66%)随机分配至帕博利珠单抗联合化疗组(n=790)或安慰剂联合化疗组(n=789)。
- 帕博利珠单抗或安慰剂200 mg静脉给药每3周一次,最多35个周期;化疗为研究者选择的氟尿嘧啶+顺铂或卡培他滨+奥沙利铂方案。
- 主要终点为总生存期,在意向治疗人群、PD-L1 CPS≥1人群和PD-L1 CPS≥10人群中评估;安全性在 as-treated 人群中评估。
主要发现
- 中位随访时间为31.0个月(IQR 23.0-38.3)。
- 意向治疗人群:帕博利珠单抗组中位总生存期12.9个月(95%CI 11.9-14.0)vs 安慰剂组11.5个月(95%CI 10.6-12.1);HR 0.78(95%CI 0.70-0.87);p<0.0001。
- PD-L1 CPS≥1人群:帕博利珠单抗组中位总生存期13.0个月(95%CI 11.6-14.2)vs 安慰剂组11.4个月(95%CI 10.5-12.0);HR 0.74(95%CI 0.65-0.84);p<0.0001。
- PD-L1 CPS≥10人群:帕博利珠单抗组中位总生存期15.7个月(95%CI 13.8-19.3)vs 安慰剂组11.8个月(95%CI 10.3-12.7);HR 0.65(95%CI 0.53-0.79);p<0.0001。
- 最常见3-5级任何原因不良事件为贫血(帕博利珠单抗组95例[12%] of 785 vs 安慰剂组76例[10%] of 787)和中性粒细胞计数降低(77例[10%] vs 64例[8%])。
关键数值与推荐
- 在意向治疗人群中,帕博利珠单抗联合化疗组中位总生存期12.9个月(95%CI 11.9-14.0)vs 安慰剂联合化疗组11.5个月(95%CI 10.6-12.1);HR 0.78(95%CI 0.70-0.87);p<0.0001。
- 在PD-L1 CPS≥1人群中,帕博利珠单抗联合化疗组中位总生存期13.0个月(95%CI 11.6-14.2)vs 安慰剂联合化疗组11.4个月(95%CI 10.5-12.0);HR 0.74(95%CI 0.65-0.84);p<0.0001。
- 在PD-L1 CPS≥10人群中,帕博利珠单抗联合化疗组中位总生存期15.7个月(95%CI 13.8-19.3)vs 安慰剂联合化疗组11.8个月(95%CI 10.3-12.7);HR 0.65(95%CI 0.53-0.79);p<0.0001。
临床怎么用
- 作者认为,帕博利珠单抗联合化疗可能作为局部晚期或转移性HER2阴性胃或胃食管结合部腺癌患者的一线治疗选择。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: PD-1 inhibitors combined with chemotherapy have shown efficacy in gastric or gastro-esophageal junction cancer. We compared the efficacy and safety of pembrolizumab plus chemotherapy with placebo plus chemotherapy in participants with locally advanced or metastatic HER2-negative gastric or gastro-esophageal junction adenocarcinoma. METHODS: KEYNOTE-859 is a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial, done at 207 medical centres across 33 countries. Eligible participants were aged 18 years and older with previously untreated histologically or cytologically confirmed locally advanced or metastatic HER2-negative gastric or gastro-esophageal junction adenocarcinoma and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients were randomly assigned (1:1) to receive pembrolizumab or placebo 200 mg, administered intravenously every 3 weeks for up to 35 cycles. All participants received investigator's choice of fluorouracil (intravenous, 800 mg/m2 per day) administered continuously on days 1-5 of each 3-week cycle plus cisplatin (intravenous, 80 mg/m2) administered on day 1 of each 3-week cycle or capecitabine (oral, 1000 mg/m2) administered twice daily on days 1-14 of each 3-week cycle plus oxaliplatin (intravenous, 130 mg/m2) administered on day 1 of each 3-week cycle. Randomisation was done using a central interactive voice-response system and stratified by geographical region, PD-L1 status, and chemotherapy in permuted block sizes of four. The primary endpoint was overall survival, assessed in the intention-to-treat (ITT) population, and the populations with a PD-L1 combined positive score (CPS) of 1 or higher, and PD-L1 CPS of 10 or higher. Safety was assessed in the as-treated population, which included all randomly assigned participants who received at least one dose of study intervention. Here, we report the results of the interim analysis. This study is registered with ClinicalTrials.gov, NCT03675737, and recruitment is complete. FINDINGS: Between Nov 8, 2018, and June 11, 2021, 1579 (66%) of 2409 screened participants were randomly assigned to receive pembrolizumab plus chemotherapy (pembrolizumab group; n=790) or placebo plus chemotherapy (placebo group; n=789). Most participants were male (527 [67%] of 790 participants in the pembrolizumab plus chemotherapy group; 544 [69%] of 789 participants in the placebo plus chemotherapy group) and White (426 [54%]; 435 [55%]). Median follow-up at the data cutoff was 31·0 months (IQR 23·0-38·3). Median overall survival was longer in the pembrolizumab group than in the placebo group in the ITT population (12·9 months [95% CI 11·9-14·0] vs 11·5 months [10·6-12·1]; hazard ratio [HR] 0·78 [95% CI 0·70-0·87]; p<0·0001), in participants with a PD-L1 CPS of 1 or higher (13·0 months [11·6-14·2] vs 11·4 months [10·5-12·0]; 0·74 [0·65-0·84]; p<0·0001), and in participants with a PD-L1 CPS of 10 or higher (15·7 months [13·8-19·3] vs 11·8 months [10·3-12·7]; 0·65 [0·53-0·79]; p<0·0001). The most common grade 3-5 adverse events of any cause were anaemia (95 [12%] of 785 participants in the pembrolizumab group vs 76 [10%] of 787 participants in the placebo group) and decreased neutrophil count (77 [10%] vs 64 [8%]). Serious treatment-related adverse events occurred in 184 (23%) participants in the pembrolizumab group and 146 (19%) participants in the placebo group. Treatment-related deaths occurred in eight (1%) participants in the pembrolizumab group and 16 (2%) participants in the placebo group. No new safety signals were identified. INTERPRETATION: Participants in the pembrolizumab plus chemotherapy group had a significant and clinically meaningful improvement in overall survival with manageable toxicity compared with participants in the placebo plus chemotherapy group. Therefore, pembrolizumab with chemotherapy might be a first-line treatment option for patients with locally advanced or metastatic HER2-negative gastric or gastro-esophageal junction adenocarcinoma. FUNDING: Merck Sharp and Dohme.
引用
- Rha SY, Oh DY, Yañez P, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023. PMID: 37875143. doi:10.1016/S1470-2045(23)00515-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。